Hiloric, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid by selectively inhibiting xanthine oxidase, which is needed to make uric acid in the body. By reducing the production of uric acid, Hiloric (Febuxostat) can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up. This can reduce the symptoms of gout. Hiloric (Febuxostat) is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.


Hiloric 40mg Tablets Each film coated tablet contains: Febuxostat 40mg Hiloric 80mg Tablets Febuxostat 80mg


Hiloric (Febuxostat) is a xanthine oxidase (XO) inhibitor indicated for chronic management of hyperuricemia in patients with chronic gout. Hiloric (Febuxostat) is not recommended for the treatment of asymptomatic hyperuricemia.


For treatment of hyperuricemia in patients with gout, Hiloric (Febuxostat) is recommended at 40mg or 80mg once daily. The recommended starting dose of Hiloric (Febuxostat) for the treatment of hyperuricemia in patients with gout is 40mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after two weeks with 40 mg, Hiloric (Febuxostat) 80 mg is recommended. Hiloric (Febuxostat) can be taken without regard to food or antacid use.


Febuxostat is contraindicated in patients with; Hypersensitivity to the active substance or to any of the excipients. In patients being treated with Azithromycin or Mercaptopurine. Asymptomatic hyperuricemia.


1. Hiloric 40mg Tablets: Alu Alu Blister Pack of 2×10’s. 2. Hiloric 40mg Tablets: Alu Alu Blister Pack of 2×10’s.

Patients should consult with their physician before taking any medicine.